Results 191 to 199 of about 4,268 (199)

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls

Clinical Pharmacology in Drug Development, 2019
Allan R Tenorio, Susan L Ford, William R Spreen   +2 more
exaly  

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

Lancet Regional Health - Europe, The
François R Girardin, Alexandra Calmy, Bernard Surial   +2 more
exaly  

PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR

2021
AKHAVEIN NIMA, CHU KEVIN, VELTHUISEN EMILE   +2 more
openaire   +1 more source

Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine

Journal of Antimicrobial Chemotherapy
Saverio Giuseppe Parisi, Maria Mazzitelli, Annemarie M J Wensing   +2 more
exaly  

FIXED DOSE COMPOSITIONS OF CABOTEGRAVIR AND RILPIVIRINE

2022
BHADAURIA PRADEEP, ALAGARSWAMY ALAGUMURUGAN, GAIKWAD DEEPAK   +2 more
openaire   +1 more source

Cabotegravir injectable PrEP approved in England and Wales

The Lancet HIV
openaire   +2 more sources

PROCESSES FOR PREPARING DOLUTEGRAVIR AND CABOTEGRAVIR AND ANALOGUES THEREOF

2016
MARAS NENAD, SELIC LOVRO, CUSAK ANJA
openaire   +2 more sources

PHARMACEUTICAL COMPOSITION OF CABOTEGRAVIR

CHU KEVIN SAM, JONES CLINTON FRANK, MUNDHRA DEEPAK BALKRISHNA, PAN RENNAN, PHILIP AUSTIN, ALIDORI SIMONE, GUPTA MANISH KUMAR, SAHA PRATIK, TASKAR PRANJAL SAMEER   +8 more
openaire   +1 more source

Cabotegravir - die Monatsspritze gegen HIV

Österreichische Apothekerzeitung, 2017
openaire   +1 more source